Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.03 and traded as high as $0.03. Mateon Therapeutics shares last traded at $0.03, with a volume of 291,652 shares trading hands.
Mateon Therapeutics Stock Performance
The company’s 50-day simple moving average is $0.03 and its 200 day simple moving average is $0.03.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Articles
- Five stocks we like better than Mateon Therapeutics
- Buy P&G Now, Before It Sets A New All-Time High
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- The Significance of Brokerage Rankings in Stock Selection
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- The Risks of Owning Bonds
- Salesforce’s Clear Path to $400 and Beyond
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
